Press release
Systemic Scleroderma Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharma
To Know in detail about the Systemic Scleroderma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Systemic Scleroderma Market Forecast
https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Systemic Scleroderma Market Report:
• The Systemic Scleroderma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The incidence and prevalence estimates of SSc in the United States were 15.1 per 100,000 person-years and 25.9 per 100,000 people, respectively, according to a study by Fan et al. (2020)
• According to Coi et al.'s analysis of the literature from 2021, the prevalence of SSc was found to be 22.2 per 100,000 people in Tuscany (Italy), with cases younger than 65 years old having the highest frequency (33.2 per 100,000, CI 95% 29.6-37.3)
• Key Systemic Scleroderma Companies: Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharmaceuticals, Certa Therapeutics, Castle Creek Biosciences, Mitsubishi Tanabe Pharma, Biocad, Prism Pharma Co., Ltd., Boehringer Ingelheim, Janssen Pharmaceutical K.K., GlaxoSmithKline, Bayer, Maruho Co., Ltd., Gesynta Pharma AB, Sanofi, and others
• Key Systemic Scleroderma Therapies: Brodalumab, MT-0551, EHP-101, KD025/Belumosudil, GS-248, Vasculan, FT011, FCX-013, MT-7117, Divozilimab, C-82, BI 685509, Guselkumab, GSK2330811, Riociguat (Adempas, BAY63-2521), nemolizumab, GS-248, SAR156597, and others
• The Systemic Scleroderma epidemiology based on gender analyzed that the female population is more prone to Systemic Scleroderma (SSc) as compared to the male population
• The Systemic Scleroderma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Systemic Scleroderma pipeline products will significantly revolutionize the Systemic Scleroderma market dynamics.
Systemic Scleroderma Overview
Systemic scleroderma, also known as systemic sclerosis (SSc), is a chronic autoimmune disease characterized by excessive collagen deposition and fibrosis (hardening and thickening of tissues) in various organs and tissues throughout the body. It is one of the subtypes of scleroderma, a group of connective tissue disorders that affect the skin, blood vessels, and internal organs.
Get a Free sample for the Systemic Scleroderma Market Report:
https://www.delveinsight.com/report-store/systemic-scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Systemic Scleroderma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Systemic Scleroderma Epidemiology Segmentation:
The Systemic Scleroderma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Systemic Scleroderma
• Prevalent Cases of Systemic Scleroderma by severity
• Gender-specific Prevalence of Systemic Scleroderma
• Diagnosed Cases of Episodic and Chronic Systemic Scleroderma
Download the report to understand which factors are driving Systemic Scleroderma epidemiology trends @ Systemic Scleroderma Epidemiology Forecast
https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Systemic Scleroderma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Scleroderma market or expected to get launched during the study period. The analysis covers Systemic Scleroderma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Systemic Scleroderma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Systemic Scleroderma Therapies and Key Companies
• Brodalumab: Kyowa Hakko Kirin
• MT-0551: Mitsubishi Tanabe Pharma Corporation
• EHP-101: Emerald Health Pharmaceuticals
• KD025/Belumosudil: Kadmon Corporation
• GS-248: Gesynta Pharma
• Vasculan: Cumberland Pharmaceuticals
• FT011: Certa Therapeutics
• FCX-013: Castle Creek Biosciences
• MT-7117: Mitsubishi Tanabe Pharma
• Divozilimab: Biocad
• C-82: Prism Pharma Co., Ltd.
• BI 685509: Boehringer Ingelheim
• Guselkumab: Janssen Pharmaceutical K.K.
• GSK2330811: GlaxoSmithKline
• Riociguat (Adempas, BAY63-2521): Bayer
• nemolizumab: Maruho Co., Ltd.
• GS-248: Gesynta Pharma AB
• SAR156597: Sanofi
Discover more about therapies set to grab major Systemic Scleroderma market share @ Systemic Scleroderma Treatment Market
https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Systemic Scleroderma Market Strengths
• Important progress has been made regarding understanding disease pathology, diagnosis, and treatment effects in Fabry disease.
• Newborn screening for Fabry disease has been implemented in several countries, enabling the early detection of individuals with Fabry mutations.
• Many therapies are under investigation in various phases of clinical trials. These include pegylated forms of α-GAL, gene therapy, and substrate reduction therapy.
Systemic Scleroderma Market Opportunities
• Challenges in diagnoses
• Development of novel therapies
• Limitations in gene therapy
• Poor disease understanding
• Clinical biomarkers
Scope of the Systemic Scleroderma Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Systemic Scleroderma Companies: Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharmaceuticals, Certa Therapeutics, Castle Creek Biosciences, Mitsubishi Tanabe Pharma, Biocad, Prism Pharma Co., Ltd., Boehringer Ingelheim, Janssen Pharmaceutical K.K., GlaxoSmithKline, Bayer, Maruho Co., Ltd., Gesynta Pharma AB, Sanofi, and others
• Key Systemic Scleroderma Therapies: Brodalumab, MT-0551, EHP-101, KD025/Belumosudil, GS-248, Vasculan, FT011, FCX-013, MT-7117, Divozilimab, C-82, BI 685509, Guselkumab, GSK2330811, Riociguat (Adempas, BAY63-2521), nemolizumab, GS-248, SAR156597, and others
• Systemic Scleroderma Therapeutic Assessment: Systemic Scleroderma current marketed and Systemic Scleroderma emerging therapies
• Systemic Scleroderma Market Dynamics: Systemic Scleroderma market drivers and Systemic Scleroderma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Systemic Scleroderma Unmet Needs, KOL's views, Analyst's views, Systemic Scleroderma Market Access and Reimbursement
To know more about Systemic Scleroderma companies working in the treatment market, visit @ Systemic Scleroderma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/systemic-scleroderma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Systemic Scleroderma Market Report Introduction
2. Executive Summary for Systemic Scleroderma
3. SWOT analysis of Systemic Scleroderma
4. Systemic Scleroderma Patient Share (%) Overview at a Glance
5. Systemic Scleroderma Market Overview at a Glance
6. Systemic Scleroderma Disease Background and Overview
7. Systemic Scleroderma Epidemiology and Patient Population
8. Country-Specific Patient Population of Systemic Scleroderma
9. Systemic Scleroderma Current Treatment and Medical Practices
10. Systemic Scleroderma Unmet Needs
11. Systemic Scleroderma Emerging Therapies
12. Systemic Scleroderma Market Outlook
13. Country-Wise Systemic Scleroderma Market Analysis (2019-2032)
14. Systemic Scleroderma Market Access and Reimbursement of Therapies
15. Systemic Scleroderma Market Drivers
16. Systemic Scleroderma Market Barriers
17. Systemic Scleroderma Appendix
18. Systemic Scleroderma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Systemic Scleroderma Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Kyowa Hakko Kirin, Mitsubishi Tanabe Pharma, Emerald Health Pharmaceuticals, Kadmon Corporation, Gesynta Pharma, Cumberland Pharma here
News-ID: 3476892 • Views: …
More Releases from DelveInsight Business Research
Major Depressive Disorder Pipeline Assessment (2024 Updates): EMA, PDMA, FDA App …
(Albany, USA) DelveInsight's, "Major Depressive Disorder Pipeline Insight" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Primary Progressive Multiple Sclerosis Pipeline Assessment (2024 Updates): EMA, …
(Albany, USA) As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Primary Progressive Multiple Sclerosis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Primary Progressive Multiple Sclerosis Pipeline Insight 2024" report…
Head and Neck Cancer Pipeline Assessment (2024 Updates): EMA, PDMA, FDA Approval …
(New York, USA) DelveInsight's 'Head and Neck Cancer Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline head and neck cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the head and neck cancer pipeline domain.
Request for a free sample report @ https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Head and Neck Cancer Pipeline Report
• DelveInsight's…
Adenoid Cystic Carcinomas Pipeline Assessment (2024 Updates): FDA Approvals, Cli …
(Las Vegas, Nevada, United States)- As per DelveInsight's assessment, globally, about 5+ key Adenoid Cystic Carcinomas companies are working on 5+ pipeline drugs in the Adenoid Cystic Carcinomas therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.
"Adenoid Cystic Carcinomas Pipeline Insight 2024"…
More Releases for Systemic
Systemic Aspergillosis and Systemic Candidiasis Market Share, Sales Channels and …
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
The systemic aspergillos is and systemic candidiasis market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019. The market is estimated to grow at a CAGR of 4.0% from 2020 to 2027.
To get sample Copy of the report, along with…
Systemic Aspergillosis and Systemic Candidasis Market Company Insights & SWOT An …
Well-research Systemic Aspergillosis and Systemic Candidasis market report serves as best help in the successful product launch strategy. It becomes easy for business participants to formulate best market strategies and plans beneficial for enhancing organization growth. Such an extensive market research report allows business players to better understand entire market environment. In order to establish the presence in the market, industries need to know more about present economic conditions and…
Systemic Aspergillosis and Systemic Candidiasis Treatment Market Insight & Futur …
(Portland, United States): Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Systemic Aspergillosis and Systemic Candidiasis Treatment Market in the latest research report added by Big Market Research. The recent research report on the global Systemic Aspergillosis and Systemic Candidiasis Treatment Market presents the latest industry data and future trends, allowing you to recognize the products and end…
Systemic Aspergillosis and Systemic Candidasis Market to Witness an Outstanding …
LOS ANGELES, UNITED STATES - The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Systemic Aspergillosis and Systemic Candidasis market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Systemic Aspergillosis and Systemic Candidasis Market. We have…
Systemic Aspergillosis and Systemic Candidiasis Market: Size & Trends Shows a Ra …
The Global Systemic Aspergillosis and Systemic Candidiasis Market is expected to reach US$ 8,247.5 million by 2027 from US$ 6,056.3 million in 2019; it is estimated to grow at a CAGR of 4% from 2021 to 2027.
Candida Auris is a fungus that poses a serious global health threat. It causes serious illness in hospitalized patients in the United States and other countries. Patients may remain colonized with C. auris for…
Systemic Aspergillosis and Systemic Candidasis Market Size, Growth, Trends | Ind …
Complete study of the global Systemic Aspergillosis and Systemic Candidasis market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Systemic Aspergillosis and Systemic Candidasis industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed…
